Chronic Phase Chronic Myelogenous Leukemia (CP-CML) Pathways

Patient Name:_____ Date of Birth:_____

Member Number: _____ Treatment Start Date:_____

Pathology:_____ **Stage**:_____

Line of Therapy: _____ **ICD-10 Code**:_____

Biomarkers/Characteristics: (select all that apply)

CML Phase: __ Chronic Phase __ Accelerated Phase __ Lymphoid Blast Phase __ Myeloid Blast Phase __ Not Reported

Imatinib resistant or intolerant: __ Yes __ No Philadelphia chromosome: __ Positive __ Negative

T315I: __ Positive __ Negative Mutation: ____V299L ___T3151

New Diagnosis of CML

- Low, Intermediate, or High-Risk Disease*****
  - ☐ Imatinib (Gleevec)
- Intermediate or High-Risk Disease*****
  - ☐ Dasatinib (Sprycel)
  - ☐ Nilotinib (Tasigna)

Second Line of Therapy (2nd Line)

- Resistant disease to primary treatment, Suboptimal Response†, or Intolerance to 1st Line
  - ☐ Bosutinib (Bosulif)
  - ☐ Dasatinib (Sprycel)
  - ☐ Nilotinib (Tasigna)
- Presence of T315I mutation
  - ☐ Ponatinib (Iclusig)

***** For patients with intermediate or high risk disease based on Sokal or Hasford score:

Sokal: Intermediate Risk=0.8-1.2; High Risk>1.2

Hasford: Intermediate Risk=781-1480; High Risk>1480

† Defined as lack of complete hematologic response or BCR-ABL1 transcripts > 10% (IS) or lack of partial cytogenetic response on bone marrow cytogenetics.

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars of reference products listed are considered "on pathway." However, reimbursement for biosimilar products may be impacted by health plan specific formularies, medical policy and preferred product rules.

carelon

8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631

Last review: 5/16/2023 | Effective date: 5/16/2023